This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vical Appoints George J. Morrow To Board Of Directors

Stocks in this article: VICL

SAN DIEGO, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that George J. Morrow, former Executive Vice President of Global Commercial Operations at Amgen, Inc., has been appointed to Vical's Board of Directors. Mr. Morrow's previous career encompassed significant accomplishments in commercial operations, sales and marketing through a progression of executive management positions at Merck & Co., Inc. and Glaxo Wellcome plc.

"We are excited to have George Morrow join our Board of Directors," said Vijay B. Samant, President and Chief Executive Officer of Vical, "especially at this inflection point in our company's progress as we prepare for the potential commercialization of Allovectin ®. George has a proven record of leadership over nearly 30 years in a series of pivotal assignments with three of the world's most successful biopharmaceutical companies. We are eager to draw on his highly relevant experience and keen insights as we advance our potentially paradigm-shifting new treatment for metastatic melanoma."

George J. Morrow

Mr. Morrow joined Amgen in 2001 as Executive Vice President, Worldwide Sales and Marketing, and advanced in 2003 to Executive Vice President, Global Commercial Operations, a position he held until his retirement in January 2011. Responsibilities in his most recent position included oversight of all commercial functions for Amgen's broad spectrum of products in more than 50 countries worldwide, and the introduction of multiple new products into global markets. From 1992 to 2001, Mr. Morrow held executive management and commercial positions within several subsidiaries of Glaxo Wellcome, including Group Vice President for Commercial Operations (U.S.), Managing Director (U.K.), and most recently as President and Chief Executive Officer of Glaxo Wellcome, Inc. (U.S.). His prior experience at Merck, from 1982 to 1992, included sales and marketing positions culminating as Vice President of Marketing.

Mr. Morrow earned a B.S. degree in chemistry from Southampton College, Long Island University; an M.S. degree in biochemistry from Bryn Mawr College; and an M.B.A. degree from Duke University's Fuqua School of Business. He is a member of the Board of Directors of Align Technology, a global medical device company, and was a member of the Board of Directors of Human Genome Sciences, Inc., a biopharmaceutical discovery and development company, from March 2011 until its acquisition in August 2012 by GlaxoSmithKline plc. Mr. Morrow has served previously on boards for Glaxo Wellcome, Inc., the Johns Hopkins School of Public Health, and the Duke University Fuqua School of Business.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs